Novo Nordisk Inc. is a major biopharmaceutical company that makes medicines, including drugs for diabetes and obesity. It lobbies Congress on Medicare and Medicaid rules, drug pricing policies (including Most Favored Nation proposals and Inflation Reduction Act implementation), obesity treatment legislation, patents and intellectual property, and budget/appropriations bills tied to health programs. The filings show in-house lobbying and about $7.2 million reported.
Show the dominant industry call, how mixed the client looks, and the allocation across the top labeled sectors.
Annual totals based on disclosed filing amounts.
Issue rankings are based on disclosed activity mentions, with filing amounts apportioned evenly across issues within the same filing.
The lobbying registrants handling this client, ranked by disclosed filing amounts.
Lobbyists are ranked by appearances and an equal share of each filing's reported amount.
ANSLEY RHYNE
The latest disclosures for this client.
NOVO NORDISK INC.
Q2NOVO NORDISK INC.
Q1The entities named in disclosed activities are the clearest available signal for where the client is aiming attention.
These contribution items line up to this client through the same lobbying firm and reporting window, and when available the same contributing lobbyist.
NOVO NORDISK INC.
SONYA CLAY
NOVO NORDISK INC.
CHAD YELINSKI
NOVO NORDISK INC.
ROSALYN KUMAR
NOVO NORDISK INC.
BRIAN BRANTON
NOVO NORDISK INC.
NOVO NORDISK INC.
Q4NOVO NORDISK INC.
Q3NOVO NORDISK INC.
Q2NOVO NORDISK INC.
Q1